Current Shingles Vaccine Landscape
The newest shingles vaccine approved by the FDA is Shingrix, a recombinant zoster vaccine developed by GlaxoSmithKline. It replaced the older live attenuated vaccine Zostavax, which is no longer distributed in the United States. Shingrix is currently the only shingles vaccine recommended by the CDC for adults aged 50 and older. It is a two-dose series administered intramuscularly in the upper arm. The CDC's Advisory Committee on Immunization Practices lists Shingrix as the preferred shingles vaccine. For financial details on GSK's product portfolio, see the company's investor relations page on GSK Investor Relations.
Shingrix demonstrated over 90% efficacy in preventing shingles in adults aged 50 and older across multiple clinical trials. Protection remains high, at approximately 85%, in adults aged 70 and older for at least four years after vaccination. The vaccine is also highly effective at preventing postherpetic neuralgia, the most common complication of shingles. CDC data shows that shingles causes painful rashes and long-term nerve pain in older adults. The vaccine's high efficacy makes it a key preventive health investment for aging populations.
Cost, Insurance Coverage, and Market Access
The average wholesale acquisition cost for Shingrix is approximately $300 per dose, making the full two-dose series around $600 before insurance. Medicare Part D plans cover Shingrix for beneficiaries aged 60 and older, though coverage specifics vary by plan. Commercial insurance plans typically cover the vaccine with no out-of-pocket cost for insured adults. Uninsured or underinsured adults may access the vaccine through the CDC's Vaccines for Adults program or manufacturer patient assistance programs. GSK provides a patient assistance program for eligible uninsured adults, which can be found on the GSK Patient Assistance website.
The shingles vaccine market is dominated by Shingrix, with Zostavax no longer available in the U.S. market. GSK reported strong global sales for Shingrix, with the vaccine generating significant revenue in the company's vaccines division. The vaccine's market position is reinforced by its high efficacy and strong CDC recommendation. For analysis on GSK's financial performance and vaccine revenue trends, see the Forbes Business Council coverage of pharmaceutical market trends.
Eligibility, Scheduling, and Public Health Impact
The CDC recommends Shingrix for all immunocompetent adults aged 50 and older, regardless of whether they have had shingles or previously received Zostavax. Adults who have already received Zostavax should wait at least two months before getting Shingrix. The vaccine is also recommended for adults who are immunocompromised or have conditions that increase shingles risk. Scheduling is done through primary care providers, pharmacies, and public health clinics. The CDC's adult immunization schedule provides the most current guidance on shingles vaccination timing and eligibility.
Public health data shows that shingles affects roughly one in three people in the United States during their lifetime. The introduction of Shingrix has significantly reduced shingles incidence and related healthcare costs in vaccinated populations. The CDC continues to monitor vaccine effectiveness and coverage rates through national health surveys. For more information on CDC recommendations and disease burden statistics, visit the CDC Shingles Vaccine Page. The vaccine's role in reducing long-term pain and healthcare utilization makes it a critical component of preventive care for older adults.